Catalent, MigVax enter deal to develop tablet vaccine for Covid-19

Catalent and Israeli biopharmaceutical firm MigVax have entered a development agreement to use the former’s Zydis Bio orally disintegrating tablet (ODT) technology for delivering the Covid-19 vaccine, MigVax-101. A lead oral vaccine programme of MigVax, MigVax-101 is an orally disintegrating freeze-dried tablet vaccine against Covid-19. It demonstrated positive data in preclinical tests. The oral formulation of the vaccine could provide substantial potential benefits in low-and middle-income nations over the existing first-generation injected vaccines. These benefits include ease of dosing, storage and transportation, the potential to address variants in the future and applicability to a wider population.